After-hours movers: Akero Therapeutics gains ahead of data, PagerDuty falls on conv. offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Juniper Networks (JNPR) headwinds position it for downside EPS risk - JPMorgan
October 10, 2023 2:30 PM EDTJPMorgan analyst Samik Chatterjee downgraded shares of Juniper Networks (NYSE: JNPR) to Neutral from Overweight, lowering the price target to $29 from $32 per share in a note Tuesday.
The analyst told investors his firm downgraded the stock as cloud and service provider headwinds position the company for downside EPS risk... More
JPMorgan Removes Akero Therapeutics (AKRO) from Analyst Focus List and Catalyst Watch, PT $62
October 10, 2023 12:35 PM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $62.00 price target on Akero Therapeutics (NASDAQ: AKRO).
The analyst comments "In our view, the totality of the SYMMETRY dataset continues to support EFX having a differentiated impact on histology across the spectrum of... More
Canaccord on Akero Therapeutics (AKRO): 'We would be strong buyers on this weakness'
October 10, 2023 8:21 AM EDTCanaccord Genuity analyst Edward Nash reiterated a Buy rating and $59.00 price target on Akero Therapeutics (NASDAQ: AKRO)
The analyst comments "Akero Therapeutics reports 36-week analysis of SYMMETRY, a 96-week Phase IIb study evaluating the efficacy and safety of its lead product candidate efruxifermin... More
Cantor Fitzgerald on Akero Therapeutics (AKRO), 'we expect the stock to trade down'
October 10, 2023 7:55 AM EDTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and $69.00 price target on Akero Therapeutics (NASDAQ: AKRO)
The analyst comments "EFX efficacy meets our mixed scenario, and we expect the stock to trade down (premarket stock is trading down 50%+, which seems an... More
